BioCentury
ARTICLE | Preclinical News

Flurry of news highlights latest in switch-controlled gene therapy

October 18, 2018 4:50 PM UTC

A series of company announcements signal advances in switch-controlled gene therapy.

uniQure N.V. (NASDAQ:QURE) and partner Synpromics Ltd. (Edinburgh, U.K.) announced preclinical data on Thursday on a liver-directed gene therapy system at the European Society of Gene & Cell Therapy (ESGCT) meeting in Lausanne. According to Synpromics, the data show that a short and highly selective liver promoter developed by Synpromics is at least eight times more potent than the current industry standard. ...